Posted on 15 December, 2009

Merus BV, a biopharmaceutical company focused on the discovery and development of mixtures of human therapeutic antibodies, today announced that it has received a grant worth € 0.67 million for the development of an antibody combination therapy for chronic inflammatory diseases using its novel OligoclonicsTM and MeMoTM technologies. The grant was awarded by EuroTransBio.
 
Merus is applying the OligoclonicsTM and MeMoTM technologies to build a pipeline of innovative human therapeutic antibodies. With these technologies, Merus generates combinations of therapeutic antibodies produced from a single cell that boast superior biological activity when compared to single antibodies. The EuroTransBio grant will allow Merus to develop innovative antibody drugs for the treatment of chronic inflammatory diseases such as Rheumatoid Arthritis.
 
Ton Logtenberg, CEO of Merus, said: “We are pleased that EuroTransBio has recognized the potential of Merus’s innovative technologies to deliver next generation therapeutics offering substantial clinical benefit to patients with chronic diseases. This grant supports collaboration between European companies and academic institutions that combine their unique expertise to achieve this goal”.